MiNK Therapeutics, Inc. (INKT) Tops Q4 EPS by 44c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of $0.23, $0.44 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results
• JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight